Inventor · disambiguated record
David J. Rawlings
Also filed as: RAWLINGS DAVID · RAWLINGS DAVID J
13 granted patents·21 pending applications·13 citations·filing 1995–2024
86Inventor score
Files withSEATTLE CHILDRENS HOSPITAL DBA SEATTLE CHILDRENS RES INST14SEATTLE CHILDRENS HOSPITAL10SEATTLE CHILDRENS HOSPITAL D/B/A SEATTLE CHILDRENS RES INSTITUTE3UNIV CALIFORNIA2CSL BEHRING L L C1
Top patents by PatentIndex Score
34 records- 0186US10745690B2Coupling endonucleases with end-processing enzymes drives high efficiency gene disruptionSEATTLE CHILDREN'S HOSPITAL·Filed 2018·Granted Aug 18, 2020·1 cites·17 claims
- 0282US12433960B2Vivo gene therapy using intraosseous delivery of a lentiviralgene constructSEATTLE CHILDRENS HOSPITAL·Filed 2024·Granted Oct 7, 2025·0 cites·13 claims
- 0382US10563226B2Enhancing endonuclease based gene editing in primary cellsSEATTLE CHILDRENS HOSPITAL·Filed 2016·Granted Feb 18, 2020·2 cites·14 claims
- 0480US12385070B2Homology directed repair compositions for the treatment of hemoglobinopathiesSEATTLE CHILDRENS HOSPITAL·Filed 2023·Granted Aug 12, 2025·0 cites·27 claims
- 0577US11713459B2Expression of FOXP3 in edited CD34+ cellsSEATTLE CHILDRENS HOSPITAL·Filed 2019·Granted Aug 1, 2023·2 cites·10 claims
- 0675US11987804B2Rapamycin resistant cellsSEATTLE CHILDRENS HOSPITAL·Filed 2019·Granted May 21, 2024·1 cites·29 claims
- 0766US2024141389A1Therapeutic genome editing in wiskott-aldrich syndrome and x-linked thrombocytopeniaSEATTLE CHILDRENS HOSPITAL DBA SEATTLE CHILDRENS RES INST·Filed 2023·Application pending·0 cites
- 0864US2024117352A1Expression of foxp3 in edited cd34+ cellsSEATTLE CHILDRENS HOSPITAL DBA SEATTLE CHILDRENS RES INST·Filed 2023·Application pending·0 cites
- 0964US2024033300A1Method for treating autoimmune disease using cd4 t-cells with engineered stabilization of expression of endogenous foxp3 geneSEATTLE CHILDRENS HOSPITAL DBA SEATTLE CHILDRENS RES INST·Filed 2023·Application pending·0 cites
- 1063US2024287452A1Engraftable cell-based immunotherapy for long-term delivery of therapeutic proteinsSEATTLE CHILDRENS HOSPITAL DBA SEATTLE CHILDRENS RES INST·Filed 2024·Application pending·0 cites
- 1163US2021228742A1In vivo gene therapy using intraosseous delivery of a lentiviralgene constructSEATTLE CHILDRENS HOSPITAL D/B/A SEATTLE CHILDRENS RES INSTITUTE·Filed 2019·Application pending·0 cites
- 1262US12110499B2Homology directed repair compositions for the treatment of hemoglobinopathiesSEATTLE CHILDRENS HOSPITAL·Filed 2018·Granted Oct 8, 2024·0 cites·18 claims
- 1362US6994975B2Expression and purification of ATM protein using vaccinia virusUNIV CALIFORNIA·Filed 2002·Granted Feb 7, 2006·1 cites·16 claims
- 1459US11643671B2Therapeutic genome editing in Wiskott-Aldrich syndrome and X-linked thrombocytopeniaSEATTLE CHILDRENS HOSPITAL·Filed 2018·Granted May 9, 2023·0 cites·17 claims
- 1559US2025369020A1Production and/or delivery of multispecific binding agentsSEATTLE CHILDRENS HOSPITAL DBA SEATTLE CHILDRENS RES INST·Filed 2023·Application pending·0 cites
- 1658US2020377911A1Enhancing endonuclease based gene editing in primary cellsSEATTLE CHILDRENS HOSPITAL DBA SEATTLE CHILDRENS RES INST·Filed 2020·Application pending·0 cites
- 1756US2025213686A1Compositions and methods for engineering treg cells for treatment of diabetesSEATTLE CHILDRENS HOSPITAL DBA SEATTLE CHILDRENS RES INST·Filed 2022·Application pending·0 cites
- 1856US2025354166A1Lentiviral vectors useful for the treatment of diseaseCSL BEHRING L L C·Filed 2022·Application pending·0 cites
- 1955US11712454B2Method for treating autoimmune disease using CD4 T-cells with engineered stabilization of expression of endogenous FOXP3 geneSEATTLE CHILDRENS HOSPITAL·Filed 2016·Granted Aug 1, 2023·0 cites·19 claims
- 2055US2025186493A1Artificial antigen-specific immunoregulatory t (airt) cellsSEATTLE CHILDRENS HOSPITAL DBA SEATTLE CHILDRENS RES INST·Filed 2021·Application pending·0 cites
- 2153US11939594B2Engraftable cell-based immunotherapy for long-term delivery of therapeutic proteinsSEATTLE CHILDRENS HOSPITAL·Filed 2018·Granted Mar 26, 2024·0 cites·15 claims
- 2253US2023272431A1Methods and compositions for editing the b2m locus in b cellsSEATTLE CHILDRENS HOSPITAL DBA SEATTLE CHILDRENS RES INST·Filed 2021·Application pending·0 cites
- 2349US2022364123A1Wiskott-aldrich syndrome gene homing endonuclease variants, compositions, and methods of useSEATTLE CHILDRENS HOSPITAL D/B/A SEATTLE CHILDRENS RES INSTITUTE·Filed 2020·Application pending·0 cites
- 2448US5550054AHematopoietic restricted tyrosine kinase (BPK)UNIV CALIFORNIA·Filed 1995·Granted Aug 27, 1996·6 cites·6 claims
- 2547US2021309995A1Homology-directed repair template design and delivery to edit hemoglobin-related mutationsSEATTLE CHILDRENS HOSPITAL DBA SEATTLE CHILDRENS RES INST·Filed 2019·Application pending·0 cites
- 2645US2021230565A1Bruton's tyrosine kinase homing endonuclease variants, compositions, and methods of useSEATTLE CHILDRENS HOSPITAL D/B/A SEATTLE CHILDRENS RES INSTITUTE·Filed 2019·Application pending·0 cites
- 2744US2022064651A1Talen-based and crispr/cas-based gene editing for bruton's tyrosine kinaseSEATTIE CHILDRENS HOSPITAL D/B/A SEATTLE CHILDRENS RES INSTITUTE·Filed 2019·Application pending·0 cites
- 2843US2023279351A1Artificial antigen-specific immunoregulatory t (airt) cellsSEATTLE CHILDRENS HOSPITAL DBA SEATTLE CHILDRENS RES INST·Filed 2020·Application pending·0 cites
- 2941US2021324381A1Therapeutic genome editing in x-linked hyper igm syndromeSEATTLE CHILDRENS HOSPITAL DBA SEATTLE CHILDRENS RES INST·Filed 2019·Application pending·0 cites
- 3037US2020009266A1In vivo gene therapy for immune deficienciesHUTCHINSON FRED CANCER RES·Filed 2018·Application pending·0 cites
- 3134US2020325458A1Optimized lentiviral vector for xla gene therapySEATTLE CHILDRENS HOSPITAL DBA SEATTLE CHILDRENS RES INST·Filed 2018·Application pending·0 cites
- 3234US2021253652A1Expression of human foxp3 in gene edited t cellsSEATTLE CHILDRENS HOSPITAL DBA SEATTLE CHILDRENS RES INST·Filed 2019·Application pending·0 cites
- 3333US10494422B2CCR5 disruption of cells expressing anti-HIV chimeric antigen receptor (CAR) derived from broadly neutralizing antibodiesSEATTLE CHILDRENS HOSPITAL·Filed 2015·Granted Dec 3, 2019·0 cites·26 claims
- 3433US2019183997A1Identification and production of high affinity igm antibodies and derivatives thereofUNIV WASHINGTON·Filed 2017·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when David J. Rawlings files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →